OZURDEX® demonstrated improved vision gains with a lighter injection schedule vs anti-VEGFs, in suitable DME patients*1
Data captured from a 2018 literature review of real world studies:*1
*Real world evidence is collected outside of controlled clinical trials and has inherent limitations including a lesser ability to control for confounding factors. Robust conclusions cannot be made in the absence of head-to-head clinical trials.
Study details
Kodjikian L et al. 2018. Data from a PubMed literature search on February 1, 2018 including 63 observational studies about the management of DME with OZURDEX® (31 studies including 1,703 eyes) and anti-VEGF (32 studies including 6,842 eyes). Only studies including more than 10 patients with a duration of more than 6 months were included. Analyses were carried out on the overall population and on subgroups to show real world efficacy outcomes and number of intravitreal injections (IVIs). Limitations of this meta-analysis include varying n numbers, definitions of visual acuity (VA) being different among some of the anti-VEGF and OZURDEX® implant studies, and difference in the proportion of suitable naïve eyes treated with OZURDEX® (1/5 of eyes were treatment naïve) and those treated with anti-VEGFs (2/3 of eyes were treatment naïve).1
In suitable DME treatment-naïve patients
OZURDEX® demonstrated improved vision gains with a lighter injection schedule vs anti-VEGFs,
due to associated underdosing of anti-VEGFs in
the real world*1
Based on a secondary analysis of subgroup data captured from a 2018 literature review of real world studies:*1
*Real world evidence is collected outside of controlled clinical trials and has inherent limitations including a lesser ability to control for confounding factors. Robust conclusions cannot be made in the absence of head-to-head clinical trials. Additional potential bias was the difference in the proportion of naïve and non-naïve eyes in OZURDEX® and anti-VEGF eyes.
OZURDEX® demonstrated vision gains in refractory DME patients*1
Based on a secondary analysis of subgroup data captured from a 2018 literature review of real world studies:*1
*Real world evidence is collected outside of controlled clinical trials and has inherent limitations including a lesser ability to control for confounding factors. Robust conclusions cannot be made in the absence of head-to-head clinical trials. Additional potential bias was the difference in the proportion of naïve and non-naïve eyes in OZURDEX® and anti-VEGF eyes.
Switching early to OZURDEX® can help your patients to achieve optimal vision outcomes*4
A retrospective, single-centre 2020 study showed patients with an insufficient response† to anti-VEGFs achieved improved vision gains with an early switch to OZURDEX®:*4
*Real world evidence is collected outside of controlled clinical trials and has inherent limitations including a lesser ability to control for confounding factors.
†An inadequate response to anti-VEGF was defined as a reduction in central subfoveal thickness (CST) or total macular volume (TMV) <10% and/or a BCVA improvement <0.1 (decimal scale).4
**A decimal VA improvement from 0.2 to 0.4 would be equivalent to a Snellen VA improvement of 20/100 to 20/50 or a LogMAR VA improvement of 0.7 to 0.4.4
Study details
Hernández Martínez A et al. 2020. A retrospective and single-centre study of 69 eyes (31 early switch; 38 late switch) treated in an ophthalmology centre in Spain, comparing the results of early (after 3 IVIs) versus late switch (after ≥6 IVIs) to OZURDEX® in patients with DME who had an insufficient response to anti-VEGFs. Three (9.7%) and 10 (26.3%) eyes have developed ocular hypertension over the course of the follow up in the early and late switch groups respectively.4
OZURDEX® offers sustained release of dexamethasone with retreatment after approximately 6 months6
Abbreviations and references
DME, diabetic macular edema; VEGF, vascular endothelial growth factor; BCVA, best corrected visual acuity; CST, central subfield thickness.
- Kodjikian L et al. BioMed Research International 2018. https://doi.org/10.1155/2018/8289253.
- Sivaprasad S and Oyetunde S. Clin Ophthalmol 2016; 24(10): 939-46.
- Ciulla TA et al. Br J Ophthalmol 2021; 105: 216-21.
- Hernández Martínez A et al. Eur J Ophthalmol 2020; 30(5): 1091-8.
- Gonzalez VH et al. Am J Ophthalmol 2016; 172: 72-9.
- OZURDEX® SPC.
- Haghjou N et al. J Ophthalmic Vis Res 2011; 6(4): 317-29.
Job Number ALL-OZU-220048. Date of Preparation March 2023
OZURDEX® (dexamethasone intravitreal implant) is indicated for the treatment of adult patients with:
- Visual impairment due to diabetic macular edema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy
- Macular edema following either branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO)
- Inflammation of the posterior segment of the eye presenting as non-infectious uveitis
Adverse events should be reported. Reporting forms and information can be found at XXXX
Adverse events should also be reported to AbbVie on GVPV@abbvie.com
Our therapy areas
Additional info
Report Adverse Event (AE reporting requirements to be localized)
This website is for Healthcare Professionals only
Job Number ALL-OZU-220048. Date of Preparation March 2023. This website has been developed and funded by AbbVie Ltd.
© 2019 AbbVie Ltd. All rights reserved. Registered number: 08004972 England.